Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

Also called NCT03593317

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03593317
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT03593317. Randomized; quadruple masking; primary purpose treatment. Start 2024-12-20 (actual); primary completion 2027-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD
Acronym
BRAVE
Condition
Arrhythmogenic Right Ventricular Dysplasia
Intervention (Drug)
Spironolactone
Intervention (Drug)
Placebo
Lead sponsor
Hospices Civils de Lyon (class: other)

Record details

Record id
cardio:ct-nct03593317
Content hash
6ad1199ac2d00f4aefa7c61cb9ebdc8669137de60e0dc86d240fbd616b65cda0